Related Experiment Video
Updated: Nov 21, 2025
Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
Toll-like receptor 7 deficiency suppresses type 1 diabetes development by modulating B-cell differentiation and
Juan Huang1,2, Jian Peng2, James Alexander Pearson2,3
1National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Toll-like receptor 7 (TLR7) deficiency delays type 1 diabetes onset in mice by altering B-cell function. These B cells suppress harmful T-cell responses, offering a potential therapeutic target for type 1 diabetes.
Area of Science:
- Immunology
- Endocrinology
- Molecular Biology
Background:
- Innate immunity, involving Toll-like receptors (TLRs), is crucial in type 1 diabetes (T1D) pathogenesis.
- The specific role of TLR7, a sensor of single-stranded RNA, in T1D development is not well understood.
Purpose of the Study:
- To investigate the role of TLR7 in the development of type 1 diabetes using a mouse model.
- To elucidate the mechanisms by which TLR7 influences immune responses relevant to T1D.
Main Methods:
- Utilized Tlr7-deficient (Tlr7-/-) and Tlr7-sufficient (Tlr7+/+) nonobese diabetic (NOD) mice.
- Analyzed B-cell differentiation, immunoglobulin production, and T-cell responses (CD4+ and CD8+).
- Assessed B-cell antigen-presenting function and MHC class I (MHC-I) expression.
Main Results:
- Tlr7-/- NOD mice showed significantly delayed T1D onset and reduced incidence.
- TLR7 deficiency altered B-cell differentiation and immunoglobulin production.
- Tlr7-/- NOD B cells suppressed diabetogenic CD4+ T-cell responses and inhibited CD8+ T-cell activation by downregulating MHC-I expression.
Conclusions:
- TLR7 plays a significant role in type 1 diabetes development by modulating B-cell function and T-cell interactions.
- Targeting TLR7 could be a potential therapeutic strategy for preventing or treating type 1 diabetes.
More Related Videos
16:26Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:22Diabetes Mellitus: Type 2 and Gestational
01:38What is the Immune System?
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...